KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cardlytics (CDLX) EBITDA Margin (2017 - 2025)

Historic EBITDA Margin for Cardlytics (CDLX) over the last 9 years, with Q3 2025 value amounting to 132.33%.

  • Cardlytics' EBITDA Margin rose 891900.0% to 132.33% in Q3 2025 from the same period last year, while for Sep 2025 it was 41.42%, marking a year-over-year increase of 574300.0%. This contributed to the annual value of 70.25% for FY2024, which is 263700.0% down from last year.
  • Cardlytics' EBITDA Margin amounted to 132.33% in Q3 2025, which was up 891900.0% from 20.22% recorded in Q2 2025.
  • Cardlytics' EBITDA Margin's 5-year high stood at 52.49% during Q1 2022, with a 5-year trough of 463.78% in Q4 2022.
  • Moreover, its 5-year median value for EBITDA Margin was 31.71% (2023), whereas its average is 72.25%.
  • Per our database at Business Quant, Cardlytics' EBITDA Margin plummeted by -4455600bps in 2022 and then soared by 3483600bps in 2023.
  • Quarter analysis of 5 years shows Cardlytics' EBITDA Margin stood at 18.22% in 2021, then crashed by -2445bps to 463.78% in 2022, then soared by 75bps to 115.43% in 2023, then soared by 90bps to 11.24% in 2024, then plummeted by -1078bps to 132.33% in 2025.
  • Its last three reported values are 132.33% in Q3 2025, 20.22% for Q2 2025, and 22.75% during Q1 2025.